Literature DB >> 7059987

Expression of multimolecular forms of pyruvate kinase in normal, benign, and malignant human breast tissue.

K H Ibsen, R A Orlando, K N Garratt, A M Hernandez, S Giorlando, G Nungaray.   

Abstract

The levels of multimolecular forms of pyruvate kinase present in four normal human breast specimens, nine benign tissues, and 13 malignant breast carcinomas were determined. The different enzymatic forms were separated by isoelectrofocusing, quantitated photometrically, and characterized further by kinetic studies using phosphoenolpyruvate as the variable substrate in the presence of different effectors. A correlation between specific activity and malignancy was found. The mean specific activities (+/- S.E.) of the normal, benign, and malignant tissues were: 0.078 +/- 0.006, 0.36 +/- 0.072, and 3.50 +/- 0.696 IU/mg protein, respectively. A form of pyruvate kinase with an isoelectric point (pI) of 7.0 predominated in the breast tissues. The properties of this form were consistent with it being the K4 isozyme, known to be widely distributed in mammalian tissues. Higher pI forms were also found. The M4 isozyme, expressed by normal muscle and brain, has a pI value similar to the highest pI form found in the breast tissues. Therefore, the pI data alone suggest that the breast specimens also express some M-type subunits. This conclusion was not supported by the kinetic data. The higher pI forms are thought to be a posttranslationally modified K isozyme. Although this modified form is found in normal specimens, it seems more prevalent in neoplasms.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7059987

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Mass spectrometry (LC-MS/MS) identified proteomic biosignatures of breast cancer in proximal fluid.

Authors:  Stephen A Whelan; Jianbo He; Ming Lu; Puneet Souda; Romaine E Saxton; Kym F Faull; Julian P Whitelegge; Helena R Chang
Journal:  J Proteome Res       Date:  2012-09-20       Impact factor: 4.466

Review 2.  PKM2, cancer metabolism, and the road ahead.

Authors:  Talya L Dayton; Tyler Jacks; Matthew G Vander Heiden
Journal:  EMBO Rep       Date:  2016-11-17       Impact factor: 8.807

3.  Microcalorimetric measurements carried out on isolated tumorous and nontumorous tissue samples from organs in the urogenital tract in comparison to histological and impulse-cytophotometric investigations.

Authors:  M Kallerhoff; M Karnebogen; D Singer; A Dettenbach; U Gralher; R H Ringert
Journal:  Urol Res       Date:  1996

Review 4.  A critical review of the role of M2PYK in the Warburg effect.

Authors:  Robert A Harris; Aron W Fenton
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-01-29       Impact factor: 10.680

5.  Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells.

Authors:  M Board; S Humm; E A Newsholme
Journal:  Biochem J       Date:  1990-01-15       Impact factor: 3.857

6.  Influence of transformation by Rous sarcoma virus on the amount, phosphorylation and enzyme kinetic properties of enolase.

Authors:  E Eigenbrodt; P Fister; H Rübsamen; R R Friis
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

7.  Levels of certain tumor markers as differential factors between bilharzial and non-biharzial bladder cancer among Egyptian patients.

Authors:  Nadia S Metwally; Sanaa A Ali; Azza M Mohamed; Hussein M Khaled; Samia A Ahmed
Journal:  Cancer Cell Int       Date:  2011-04-07       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.